Table 1.
Patients' characteristics
| Patient (Gender/Age) | Diagnosis | IAHG Score | Autoantibodies (titer) | ALT (<0.85μmol/s.L) | ALP (<2.15μmol/s.L) | HAI | Fibrosis | Therapy | Res- | ||||||
| ANA | SMA | ANCA | AMA | (Ref. 6) | (wk) | ponse | |||||||||
| pre- | post- | pre- | post- | pre- | post- | ||||||||||
| Budesonide | Budesonide | Budesonide | |||||||||||||
| First-line therapy | |||||||||||||||
| B.M-L. (F/65) | AIH-PBC | 19 | 1280 | - | - | - | 15.18 | 0.22 | 7.12 | 1.44 | 5 | 3 | 3 | 241 | CR |
| D.B. (M/26) | AIH | 14 | 320 | - | - | - | 16.4 | 0.78 | 3.19 | 0.95 | 7 | nd | 4 | 36 | CR |
| D.C. (F/49) | AIH | 22 | 640 | - | - | - | 1.91 | 0.89 | 3.89 | 3.53 | 4 | nd | 5 | 24 | NR/AE |
| H-S.M. (F/31) | AIH | 17 | 160 | 80 | - | - | 4.43 | 0.6 | 1.62 | 0.9 | 7 | nd | 2 | 50 | CR |
| K.M. (F/62) | AIH | 14 | - | - | - | - | 3.45 | 3.59 | 7.86 | 6.29 | 5 | nd | 4 | 122 | NR |
| L.M. (M/60) | AIH | 16 | 640 | 640 | - | - | 4.1 | 0.35 | nd | nd | 1 | nd | 0 | 82 | CR |
| N.G. (F/64) | AIH-PBC | 12 | 2560 | - | - | 640 | 10.73 | 0.38 | 7.53 | 1.63 | 11 | 1 | 0 | 82 | CR |
| S.T. (M/40) | AIH | 12 | - | - | >80 | - | 8.39 | 0.57 | 7.84 | 1.36 | 1 | nd | 0 | 24 | CR |
| T.H. (F/50) | AIH | 19 | 640 | 160 | - | - | 3.38 | 6.77 | 1.54 | 1.74 | 9 | nd | 3 | 42 | NR |
| T.E. (F/49) | AIH-PBC | 15 | - | 640 | - | 1280 | 2.27 | 0.58 | 4.21 | 1.61 | 5 | 2 | 5 | 112 | CR |
| Second-line therapy | |||||||||||||||
| B.R. (M/39) | AIH | 14 | 160 | - | - | - | 4.42 | 0.6 | 2.16 | 0.63 | 6 | 2 | 1 | 100 | CR |
| B.S. (F/25) | AIH | 17 | 160 | - | - | - | 16.48 | 0.41 | 4.89 | 1.38 | 6 | 1 | 3 | 116 | CR |
| D.H. (F/61) | AIH-PBC | 14 | >2560 | - | - | -3 | 2.37 | 0.45 | 11.91 | 1.24 | 5 | 3 | 4 | 32 | CR |
| F.C. (F/41) | AIH | 17 | 2560 | 2560 | - | 320 | 10.1 | 0.55 | 4.6 | 0.88 | 6 | nd | 2 | 72 | CR |
| G.W. (M/68) | AIH-PBC | 6 | - | - | - | - | 28.65 | 0.18 | 4.1 | 0.77 | 3 | nd | 4 | 110 | CR |
| K.C. (F/40) | AIH | 16 | 640 | 160 | - | - | 10.1 | 0.68 | 4.6 | 1.77 | 4 | nd | 1 | 50 | CR |
| S.H-D. (M/64) | AIH-PSC | 11 | 2560 | - | - | - | 2.01 | 0.6 | 30.13 | 2.3 | 4 | 1 | 1 | 80 | CR |
| S.U. (F/41) | AIH-PSC | 14 | 1280 | - | - | - | 20 | 0.3 | 5.1 | 1.65 | 6 | nd | 1 | 124 | CR |
CR = complete response; NR = no response; ANA = antinuclear antibodies; SMA = antibodies to smooth muscle; AMA = antimitochondrial antibodies; ANCA = antineutrophil cytoplasmic antibodies; 3 = anti-Sp100 positive; PSC = primary sclerosing cholangitis; PBC = primary biliary cirrhosis; ALT = alanine aminotransferase; ALP = alkaline phosphatase; AE=adverse event; HAI = Hepatitis Activity Index; 1 = the therapy was continued with azathioprine; 2=discontinuation of the therapy because of no response;